On 6 June 2017, the World Health Organization (WHO) published updates to its ‘Essential Medicines List’ (EML). Read more here.

Eurosurveillance is on the updated list of the Directory of Open Access Journals and in the SHERPA/RoMEO database. Read more here.

Follow Eurosurveillance on Twitter: @Eurosurveillanc

Back to All Announcements
Next Next

WHO updates its Essential Medicines List

On 6 June 2017, the World Health Organization (WHO) published updates to its ‘Essential Medicines List’ (EML). Read more here.

On 6 June 2017, the World Health Organization (WHO) published updates to its ‘Essential Medicines List’ (EML). The updates include new advice on the use of antibiotics and the addition of 55 medicines, including new drugs for hepatitis C, HIV, tuberculosis, cancer and pain relief, to the list. 

In the most comprehensive update of the antibiotics section in the 40-year history of existence of the EML, the WHO groups antibiotics into three categories and issues advice of when the medicines in the respective categories shall be used. The aim of the grouping and the recommendations for use is that the medicines in the three respective categories (ACCESS, WATCH and RESERVE) is twofold: to ensure that antibiotics are available when needed and that the right antibiotics be prescribed for the right infections.  

Some 10 antibiotics have been added to the list for adults, and 12 to the list for children. Furthermore, the updated EML includes two new drugs to fight leukaemia, a new combination therapy against hepatitis C, a pre-exposure prophylaxis to prevent HIV infection, two new drugs to treat children, adolescents and adults with multidrug-resistant tuberculosis (MDR-TB), new formulations for the treatment of paediatric TB and finally fentanyl and methadone for pain relief in cancer patients. 

Read more about the update here: 

Find the updated list here:

Back to All Announcements
Next Next

The publisher’s policy on data collection and use of cookies.

Disclaimer: The opinions expressed by authors contributing to Eurosurveillance do not necessarily reflect the opinions of the European Centre for Disease Prevention and Control (ECDC) or the editorial team or the institutions with which the authors are affiliated. Neither ECDC nor any person acting on behalf of ECDC is responsible for the use that might be made of the information in this journal. The information provided on the Eurosurveillance site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. Our website does not host any form of commercial advertisement. Except where otherwise stated, all manuscripts published after 1 January 2016 will be published under the Creative Commons Attribution (CC BY) licence. You are free to share and adapt the material, but you must give appropriate credit, provide a link to the licence, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

Eurosurveillance [ISSN] - ©2007-2016. All rights reserved

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.